Journal article
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study
HC Diener, RL Sacco, S Yusuf, D Cotton, S Ôunpuu, WA Lawton, Y Palesch, RH Martin, GW Albers, P Bath, N Bornstein, BP Chan, ST Chen, L Cunha, B Dahlöf, J De Keyser, GA Donnan, C Estol, P Gorelick, V Gu Show all
Lancet Neurology | ELSEVIER SCIENCE INC | Published : 2008
Abstract
Background: The treatment of ischaemic stroke with neuroprotective drugs has been unsuccessful, and whether these compounds can be used to reduce disability after recurrent stroke is unknown. The putative neuroprotective effects of antiplatelet compounds and the angiotensin II receptor antagonist telmisartan were investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial. Methods: Patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80 mg telmisartan or placebo once per da..
View full abstractGrants
Awarded by National Institute of Neurological Disorders and Stroke
Funding Acknowledgements
Boehringer Ingelheim; Bayer-Schering Pharma (in selected countries); GlaxoSmithKIine (in selected countries).